A paired analysis of pre-venetoclax and venetoclax progression in 15 CLL patients revealed a de novo Bcl-2 mutation, changing residue Gly101 in Val in 7 CLL patients [32]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.